Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

September 2016

Feature

Research Reports
Associations Between Pre- and Post-Cancer Depression Diagnoses and End-of-Life Cancer Care Intensity
09/06/2016
Kathy Doan, MPH
Becca R Levy, PhD
Cary P Gross, MD
Shi-Yi Wang, MD, PhD
Abstract: Literature suggests that depression has adverse effects on health outcomes among patients with cancer. However, the associations between depression and end-of-life (EOL) cancer care are inconclusive. In...
Abstract: Literature suggests that depression has adverse effects on health outcomes among patients with cancer. However, the associations between depression and end-of-life (EOL) cancer care are inconclusive. In...
...
09/06/2016
Journal of Clinical Pathways

Column

Counterpoint
The Pivot Toward Patient-Centeredness in Medicine and Oncology
09/06/2016
Bruce Feinberg, DO
Julia Braverman, PhD
Jennifer Fillman, MBA
Patient-reported outcome (PRO) research has shown that PROs must play a role in the future of health care delivery as the system transitions from volume-based care to value-based care. Building trust among...
Patient-reported outcome (PRO) research has shown that PROs must play a role in the future of health care delivery as the system transitions from volume-based care to value-based care. Building trust among...
...
09/06/2016
Journal of Clinical Pathways
Counterpoint
Incorporating Routine Patient-Reported Outcomes Assessment Into Cancer Care: Building Momentum
09/06/2016
Edward Stepanski, PhD
While the collection and reporting of patient-reported outcome data in oncology trials and care settings has yet to reach its full potential, it has made some progress in recent years. Patient-reported outcomes...
While the collection and reporting of patient-reported outcome data in oncology trials and care settings has yet to reach its full potential, it has made some progress in recent years. Patient-reported outcomes...
While...
09/06/2016
Journal of Clinical Pathways
Viewpoint
The Limitations of Patient-Reported Outcome Measurement in Oncology
09/06/2016
Stephen P McKenna, PhD, AFBPsS, CPsychol
Generic patient-reported outcome measures (PROMs) for cancer have outlived their utility. More relevant and accurate PROMs are required in order to demonstrate the true value of oncology interventions to...
Generic patient-reported outcome measures (PROMs) for cancer have outlived their utility. More relevant and accurate PROMs are required in order to demonstrate the true value of oncology interventions to...
...
09/06/2016
Journal of Clinical Pathways
Clinical Pathways GPS
Population Health Delivery Through Health Systems and Pharma
09/06/2016
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Scott Guerin, PhD
As health systems become more prevalent, they are having increasing levels of control over treatment decisions, in coordination with physicians and managed care organizations. As a result of this increased level of...
As health systems become more prevalent, they are having increasing levels of control over treatment decisions, in coordination with physicians and managed care organizations. As a result of this increased level of...
As...
09/06/2016
Journal of Clinical Pathways
Pharma Insights
Clarity Regarding Prostate Cancer Screening, Why Payers Need It Too
09/06/2016
Jeremy Schafer, PharmD, MBA
Controversy over the lack of a survival benefit associated with early diagnosis of prostate cancer through prostate-specific antigen (PSA) screening has led to uncertainty in the determination of PSA coverage and its...
Controversy over the lack of a survival benefit associated with early diagnosis of prostate cancer through prostate-specific antigen (PSA) screening has led to uncertainty in the determination of PSA coverage and its...
...
09/06/2016
Journal of Clinical Pathways

Insights

Interview
Do Value Frameworks Benefit Patients?
09/06/2016
Jonathan Wilcox
An interview with Jonathan Wilcox, co-founder and policy director, Patients Rising, Washington, DC In an effort to address rising health care costs, a number of organizations have spearheaded the development of...
An interview with Jonathan Wilcox, co-founder and policy director, Patients Rising, Washington, DC In an effort to address rising health care costs, a number of organizations have spearheaded the development of...
An...
09/06/2016
Journal of Clinical Pathways
Interview
How Financial Distress Can Affect Cancer Care
09/06/2016
Christopher S Lathan, MD, MS, MPH
An interview with Christopher S Lathan, MD, MS, MPH, assistant professor of medicine, Harvard Medical School; faculty director, Cancer Care Equity Program; medical director, Dana-Farber Cancer Institute at St...
An interview with Christopher S Lathan, MD, MS, MPH, assistant professor of medicine, Harvard Medical School; faculty director, Cancer Care Equity Program; medical director, Dana-Farber Cancer Institute at St...
An...
09/06/2016
Journal of Clinical Pathways

Department

Research in Review
Mayo Clinic Outlines Pathways for Thrombotic Microangiopathies
09/06/2016
JCP Editors
Members of the Mayo Clinic in Rochester, MN, have provided guidelines for the creation of evidence-based clinical pathways for thrombotic microangiopathies (TMAs). TMAs are a diverse set of disorders sharing a...
Members of the Mayo Clinic in Rochester, MN, have provided guidelines for the creation of evidence-based clinical pathways for thrombotic microangiopathies (TMAs). TMAs are a diverse set of disorders sharing a...
...
09/06/2016
Journal of Clinical Pathways
Research in Review
Addition of Panobinostat to Multiple Myeloma Care Has Little Economic Impact
09/06/2016
JCP Editors
Adding panobinostat to treatment regimens for multiple myeloma would have a minimal economic impact and could even save the health care system money, claims a study published in the Journal of Managed Care &...
Adding panobinostat to treatment regimens for multiple myeloma would have a minimal economic impact and could even save the health care system money, claims a study published in the Journal of Managed Care &...
Adding...
09/06/2016
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

September 2016 Volume 2

View Issue Archive
Editorial Correspondence

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement